It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Neuroinflammation in the brain contributes to the pathogenesis of Parkinson’s disease (PD), but the potential dysregulation of peripheral immunity has not been systematically investigated for idiopathic PD (iPD). Here we showed an elevated peripheral cytotoxic immune milieu, with more terminally-differentiated effector memory (TEMRA) CD8 T, CD8+ NKT cells and circulating cytotoxic molecules in fresh blood of patients with early-to-mid iPD, especially females, after analyzing > 700 innate and adaptive immune features. This profile, also reflected by fewer CD8+FOXP3+ T cells, was confirmed in another subcohort. Co-expression between cytotoxic molecules was selectively enhanced in CD8 TEMRA and effector memory (TEM) cells. Single-cell RNA-sequencing analysis demonstrated the accelerated differentiation within CD8 compartments, enhanced cytotoxic pathways in CD8 TEMRA and TEM cells, while CD8 central memory (TCM) and naïve cells were already more-active and transcriptionally-reprogrammed. Our work provides a comprehensive map of dysregulated peripheral immunity in iPD, proposing candidates for early diagnosis and treatments.
Men are at a greater risk to develop Parkinson’s disease (PD). However, Hefeng and team revealed enhanced cytotoxicity and terminal differentiation in CD8 T cells of early-to-mid stage idiopathic PD, especially for females, using systems immunology.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details














1 Luxembourg Institute of Health (LIH), Department of Infection and Immunity, Esch-sur-Alzette, Luxembourg (GRID:grid.451012.3) (ISNI:0000 0004 0621 531X); University of Luxembourg, Faculty of Science, Technology and Medicine, Esch-sur-Alzette, Luxembourg (GRID:grid.16008.3f) (ISNI:0000 0001 2295 9843); ETH Zurich, Institute of Microbiology, Zurich, Switzerland (GRID:grid.5801.c) (ISNI:0000 0001 2156 2780)
2 Luxembourg Institute of Health (LIH), Department of Infection and Immunity, Esch-sur-Alzette, Luxembourg (GRID:grid.451012.3) (ISNI:0000 0004 0621 531X); Eligo Bioscience, Paris, France (GRID:grid.503190.e)
3 Luxembourg Institute of Health (LIH), National Cytometry Platform, Esch-sur-Alzette, Luxembourg (GRID:grid.451012.3) (ISNI:0000 0004 0621 531X)
4 University of Luxembourg, Luxembourg Centre for Systems Biomedicine (LCSB), Belvaux, Luxembourg (GRID:grid.16008.3f) (ISNI:0000 0001 2295 9843); Centre Hospitalier de Luxembourg (CHL), Parkinson Research Clinic, Luxembourg, Luxembourg (GRID:grid.418041.8) (ISNI:0000 0004 0578 0421)
5 University of Luxembourg, Luxembourg Centre for Systems Biomedicine (LCSB), Belvaux, Luxembourg (GRID:grid.16008.3f) (ISNI:0000 0001 2295 9843); Centre Hospitalier de Luxembourg (CHL), Parkinson Research Clinic, Luxembourg, Luxembourg (GRID:grid.418041.8) (ISNI:0000 0004 0578 0421); Luxembourg Institute of Health (LIH), Transversal Translational Medicine, Strassen, Luxembourg (GRID:grid.451012.3) (ISNI:0000 0004 0621 531X)
6 University of Luxembourg, Luxembourg Centre for Systems Biomedicine (LCSB), Belvaux, Luxembourg (GRID:grid.16008.3f) (ISNI:0000 0001 2295 9843)
7 University of Luxembourg, Luxembourg Centre for Systems Biomedicine (LCSB), Belvaux, Luxembourg (GRID:grid.16008.3f) (ISNI:0000 0001 2295 9843); Icahn School of Medicine at Mount Sinai, New York, USA (GRID:grid.59734.3c) (ISNI:0000 0001 0670 2351)
8 Luxembourg Institute of Health (LIH), Department of Infection and Immunity, Esch-sur-Alzette, Luxembourg (GRID:grid.451012.3) (ISNI:0000 0004 0621 531X)
9 Luxembourg Institute of Health (LIH), Department of Infection and Immunity, Esch-sur-Alzette, Luxembourg (GRID:grid.451012.3) (ISNI:0000 0004 0621 531X); University of Luxembourg, Faculty of Science, Technology and Medicine, Esch-sur-Alzette, Luxembourg (GRID:grid.16008.3f) (ISNI:0000 0001 2295 9843); Luxembourg Institute of Health (LIH), Transversal Translational Medicine, Strassen, Luxembourg (GRID:grid.451012.3) (ISNI:0000 0004 0621 531X)
10 Luxembourg Institute of Health (LIH), Transversal Translational Medicine, Strassen, Luxembourg (GRID:grid.451012.3) (ISNI:0000 0004 0621 531X)
11 Luxembourg Institute of Health (LIH), Department of Infection and Immunity, Esch-sur-Alzette, Luxembourg (GRID:grid.451012.3) (ISNI:0000 0004 0621 531X); University of Luxembourg, Faculty of Science, Technology and Medicine, Esch-sur-Alzette, Luxembourg (GRID:grid.16008.3f) (ISNI:0000 0001 2295 9843)
12 Integrated Biobank of Luxembourg (IBBL), Luxembourg Institute of Health (LIH), Dudelange, Luxembourg (GRID:grid.451012.3) (ISNI:0000 0004 0621 531X); Université Paris Cité, CRBIP, Institut Pasteur, Paris, France (GRID:grid.508487.6) (ISNI:0000 0004 7885 7602)
13 University of Luxembourg, Luxembourg Centre for Systems Biomedicine (LCSB), Belvaux, Luxembourg (GRID:grid.16008.3f) (ISNI:0000 0001 2295 9843); University of Luxembourg, Department of Physics and Material Science, Luxembourg, Luxembourg (GRID:grid.16008.3f) (ISNI:0000 0001 2295 9843); University California San Diego School of Medicine, Department of Neurosciences, La Jolla, USA (GRID:grid.266100.3) (ISNI:0000 0001 2107 4242)
14 University of Luxembourg, Luxembourg Centre for Systems Biomedicine (LCSB), Belvaux, Luxembourg (GRID:grid.16008.3f) (ISNI:0000 0001 2295 9843); University of Bonn, Institute of Molecular Psychiatry, Bonn, Germany (GRID:grid.10388.32) (ISNI:0000 0001 2240 3300)
15 Luxembourg Institute of Health (LIH), Department of Infection and Immunity, Esch-sur-Alzette, Luxembourg (GRID:grid.451012.3) (ISNI:0000 0004 0621 531X); Odense Research Center for Anaphylaxis (ORCA), University of Southern Denmark, Department of Dermatology and Allergy Center, Odense, Denmark (GRID:grid.10825.3e) (ISNI:0000 0001 0728 0170)
16 Luxembourg Institute of Health (LIH), Department of Infection and Immunity, Esch-sur-Alzette, Luxembourg (GRID:grid.451012.3) (ISNI:0000 0004 0621 531X); Data Integration and Analysis Unit, Luxembourg Institute of Health (LIH), Strassen, Luxembourg (GRID:grid.451012.3) (ISNI:0000 0004 0621 531X)